Mangoceuticals, Inc. has been actively engaging in corporate developments throughout the first half of 2024, including the issuance of securities, entering consulting and employment agreements, and other significant corporate activities. The company has issued shares of restricted common stock as compensation in consulting agreements with entities such as Luca Consulting, LLC, First Level Capital, and G&P General Consulting. Key employment agreements have been executed, including an extension with Luca Consulting, LLC, and a new agreement with Zvonimir Moric for strategic partnership development. Mangoceuticals also completed a follow-on offering of common stock and exercised an over-allotment option, which included the issuance of warrants to underwriters. The company designated Series B and C Convertible Preferred Stock, with sales of Series...Show More

Mangoceuticals, Inc. has been actively engaging in corporate developments throughout the first half of 2024, including the issuance of securities, entering consulting and employment agreements, and other significant corporate activities. The company has issued shares of restricted common stock as compensation in consulting agreements with entities such as Luca Consulting, LLC, First Level Capital, and G&P General Consulting. Key employment agreements have been executed, including an extension with Luca Consulting, LLC, and a new agreement with Zvonimir Moric for strategic partnership development. Mangoceuticals also completed a follow-on offering of common stock and exercised an over-allotment option, which included the issuance of warrants to underwriters. The company designated Series B and C Convertible Preferred Stock, with sales of Series B Preferred Stock to an institutional accredited investor and the issuance of Series C Preferred Stock for the acquisition of patents. There have been multiple conversions of Series B Preferred Stock into common stock. Additionally, the CEO-controlled entities have provided loans to the company, and a Patent Purchase Agreement was made with Intramont Technologies, Inc. for infection prevention patents. Mangoceuticals has also established subsidiaries in Mexico and the UK, though operations there are limited as of June 30, 2024. Despite these developments, the company reported a net loss for the six months ended June 30, 2024, and included going concern considerations in its financial statements. Subsequent to the reporting period, Mangoceuticals has entered into additional consulting agreements, preferred stock conversions, and corporate agreements for product distribution and marketing.